GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma
Shots:
- The P-III trials for depemokimab in severe asthma includes SWIFT-1, SWIFT-2 & an OLE AGILE studies. SWIFT-1 & 2 studies evaluate the safety & efficacy as an adjunctive therapy vs PBO in patients (n=375 & n=380) with type 2 inflammation. Another NIMBLE trial is ongoing in patients switching from mepolizumab/benralizumab
- The (SWIFT) trials reached the 1EPs, showing reduced annualized rate of asthma exacerbations over 52wks. with similar incidence & severity of TEAEs b/w depemokimab & PBO. Further analysis is underway to support regulatory submissions & will be highlighted at future conferences
- Depemokimab is an ultra-long-acting biologic that works by binding with high potency to IL-5, a cytokine in type 2 inflammation, allowing 6mos. dosing intervals for severe asthma patients
Ref: GSK | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
